



Medicines Patent Pool Governance Board Meeting #33

November 10th – 11th, 2022
In-person meeting

Attendees

Governance Board Members:

Marie-Paule Kieny (Chair), Mojisola Christianah Adeyeye, Manica Balasegaram, Pushpa Vijayaraghavan, Peter Maybarduk, John-Arne Røttingen, Maximiliano Santa Cruz.

Excused Board Members:

Patrizia Carlevaro, Alexandra Volgina

Non-voting members:

Peter Beyer – EAG Chair, Vincent Bretin – Unitaid Executive Team, Katherine Hencher – Unitaid Executive Team, Karin Timmermans – Unitaid Strategy Team, Marion (Amy) Dietterich – WIPO Observer, Antony Scott Taubman – WTO Observer.

Excused non-voting participants:

Mariângela Batista Galvão Simão – WHO Observer

Medicines Patent Pool Foundation Management Team:

Charles Gore – Executive Director, Esteban Burrone – Head of Policy, Jane Caldwell – Head of Operations and Resources, Ike James – Head of Technology Transfer, Gelise McCullough – Head of Communications, Sandra Nobre – Head of Business Development, Chan Park – General Counsel, Gosha Stehle – HR Manager, and Agnese Tonnina – Grants and Operations Manager.

Summary of Decisions

The Governance Board of the Medicines Patent Pool:

1. Approves the agenda of the Governance Board Meeting #34.
2. In the context of the 2023-2025 Strategy, agrees with the finalised strategic framework and the following five strategic goals presented by Management: 1. Expand access to medicines for infectious diseases; 2. Establish voluntary licensing as an impactful access mechanism for other diseases and conditions; 3. Facilitate development and access to novel medical technologies; 4. Accelerate equitable access to countermeasures for pandemics and other international health emergencies; 5. Support diversified and sustainable manufacturing capacity in LMICs.
3. Agrees with adding the following elements to complement the 2023-2025 strategic directions set during the June Board retreat: other infectious diseases including antimicrobials (AMR), inclusion of viral hepatitis (beyond Hepatitis C – MPP already had licences for product also indicated for hepatitis B), maternal health, regulatory information, and ambition to become carbon neutral.
4. Approves the changes in the Finance Policy.
5. Approves the changes in the list of accesses to HDFC bank in India.
6. Approves all the changes resulting from the Management review of the risk register, including the inclusion of Risk 49 on Sexual Exploitation, Abuse and Harassment (SEAH).
7. Approves the extension of Board Members' terms of office to 3 years, renewable twice, to a maximum of nine years. Existing terms will not be affected by this amendment, which will be applied only to new or to be renewed terms of office.
8. Invites Mojisola Adeyeye, John-Arne Røttingen, and Peter Maybarduk to serve for a second term of 3 years. Both Ms. Adeyeye and Mr. Røttingen will start their second terms on 1 December 2022. Mr. Maybarduk will start his second term on 1 April 2023.
9. Agrees to invite John-Arne Røttingen to serve as Chair of the Strategy and Partnerships Committee.
10. Agrees that Peter Maybarduk should be added as a Member of the Governance Committee
11. In light of upcoming changes at senior level at WHO and in order to ensure continued leadership for the mRNA Technology Transfer Hub Programme, exceptionally asks Marie-Paule Kieny to remain on the MPP Board for one more term of three years, when her term expires next year, to which Marie-Paule Kieny agrees.
12. Thanks Manica Balasegaram for his huge contribution during his six years of service as Board Member and recently as Chair of the Strategy and Partnerships Committee.